(Q46841504)

25 December 2017

title

No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis (English)

1 reference

25 December 2017

Frank Reimann

3

0 references

Fiona Gribble

object named as

Fiona M Gribble

4

0 references

Ewan Pearson

object named as

Ewan R Pearson

6

0 references

author name string

Josie M M Evans

1

1 reference

25 December 2017

Simon A Ogston

2

1 reference

25 December 2017

Andrew D Morris

5

1 reference

25 December 2017

publication date

17 December 2007

1 reference

25 December 2017

Diabetes, Obesity and Metabolism

published in

1 reference

25 December 2017

volume

10

1 reference

25 December 2017

issue

4

1 reference

25 December 2017

page(s)

350-352

1 reference

25 December 2017

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

Sulphonylurea action revisited: the post-cloning era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00833.X

Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18093208

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1463-1326.2007.00833.X

1 reference

25 December 2017

PMC publication ID

7237236

0 references

1 reference

25 December 2017